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Abstract 
Synapse loss is an early event in late-onset Alzheimer’s disease (LOAD). In this study we have 
assessed the capacity of a polygenic risk score (PRS) restricted to synapse-encoding loci to predict 
LOAD. We used summary statistics from the IGAP genome-wide association meta-analysis of 74,046 
subjects for model construction and tested the “Synaptic PRS” in two independent datasets of controls 
and pathologically-confirmed LOAD. The mean Synaptic PRS was 2.3-fold higher in LOAD 
compared to controls (p<0.0001) with a predictive accuracy of 72% in the target dataset (n=439) and 
73% in the validation dataset (n=136), a 5-6% improvement compared to the APOE locus 
(p<0.00001). The model comprises 8 variants from 4 previously-identified (BIN1, PTK2B, PICALM, 
APOE) and 2 novel (DLG2, MINK1) LOAD loci involved in glutamate signaling (p=0.01) or APP 
catabolism/tau binding (p=0.005). As the simplest PRS model with good predictive accuracy to 
predict LOAD, we conclude that synapse-encoding genes are enriched for LOAD risk-modifying loci. 
The Synaptic PRS could be used to identify individuals at risk of LOAD before symptom onset.  
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1. Background 
The genetic component of early–onset familial AD is attributed to genetic variants in the APP, PSEN1 
and PSEN2 genes, all of which are central to the amyloid cascade hypothesis (Hardy and Selkoe, 
2002). The most prominent late-onset AD (LOAD) risk locus (APOE) was detected almost 30 years 
ago (Pericak-Vance, et al., 1991). The ε4 allele of APOE confers a 3-fold increased risk for AD in 
heterozygous carriers increasing to up to 12-fold in the homozygous state (Corder, et al., 1993). The 
development of single nucleotide polymorphism (SNP) arrays has enabled genome-wide association 
studies (GWAS) of increasing sample size followed by meta-analyses of multiple datasets to discover 
many new AD associated loci. In 2019, The International Genetics of Alzheimer’s project (IGAP) 
reported the largest meta-analysis of case-control studies (over 80,000 subjects) so far (Kunkle, et al., 
2019). Additionally, several rare variants have been characterized by next generation sequencing 
approaches. Collectively, these approaches have led to the identification of over 40 loci that modify 
the risk of AD (de Rojas, et al., 2019,Guerreiro, et al., 2013,Harold, et al., 2009,Jonsson, et al., 
2012,Jonsson, et al., 2013,Lambert, et al., 2013,Seshadri, et al., 2010,Sims, et al., 2017). However 
these signals cannot not explain the entire genetic component of LOAD and suggest a substantial 
‘missing heritability’ (Ridge, et al., 2016). 
One concept that has been gaining traction more recently is the idea that the combined effect of many 
loci of smaller effect, both common and rare, in addition to the currently known AD associated 
variants might explain some of the missing genetic risk (Purcell, et al., 2009). This effect can be 
estimated by generation of a polygenic risk score (PRS) (Abraham and Inouye, 2015,Escott-Price, et 
al., 2015,Torkamani, et al., 2018). Several studies have reported PRS with good accuracy to predict 
LOAD (Chaudhury, et al., 2018,Tan, et al., 2018,Tan, et al., 2017,van der Lee, et al., 2018) or 
conversion from mild cognitive impairment (Adams, et al., 2015,Chaudhury, et al., 2019,Rodriguez-
Rodriguez, et al., 2013). That being said, these PRS are typically comprised of hundreds or even 
thousands of loci, thereby limiting their utility as an early screening tool to identify individuals at 
high-risk for developing AD. Restricting PRS to loci implicated in pathways central to LOAD 
pathogenesis, could lead to simpler PRS models. As synapse loss is an early event in AD (Selkoe, 
2002) and the best pathological correlate for cognitive decline (Terry, et al., 1991), we hypothesized 
that variability in genes that encode proteins integral to synaptic function may be enriched for genetic 
variants with small effect size, whose cumulative effect may have high predictive capacity for 
identifying individuals susceptible to LOAD.  
In this study we have used summary statistics from a large reference GWAS dataset (74,046 subjects) 
to determine the optimal PRS restricted to synaptic loci (henceforth termed, Synaptic PRS). We have 
determined the predictive capacity of the Synaptic PRS in two datasets of cognitively normal controls 
(target dataset; n=137, validation dataset; n=80) and pathologically confirmed LOAD patients (target 
dataset; n=302, validation dataset; n=56) from the Brains for Dementia Research (BDR) resource. 
Furthermore, we have compared the predictive capacity to that of a previously reported PRS 
comprising the top genome-wide association loci on the Neurochip platform (Neurochip PRS) (Lleo, 
et al., 2019).  
2. Methods 
2.1. Patient Samples 
Experimental procedures were approved by local ethics committees - Nottingham Research Ethics 
Committee 2 (REC reference 04/Q2404/130); London – City and East NRES (REC reference 
08/H0704/128+5) and completed in accordance with approved guidelines. All donors gave written 
informed consent as governed by local guidelines. The DNA samples used in this study were 
extracted from autopsied brain tissue prospectively selected from Batch 1 and 2 (target dataset) and 
Batch 3 (validation dataset) from the BDR resource (Brookes, et al., 2018). Samples recruited for the 
control group were from cognitively normal subjects with a clinical dementia rating of 0 (target 
dataset; n=137, validation dataset; n=80). LOAD patients had a clinical diagnosis of dementia due to 
AD and neuropathological confirmation of AD pathology (target dataset; n=302, validation dataset; 
n=56).  
2.2. Sample preparation and genotyping 
DNA from the BDR resource was extracted using a standard phenol chloroform method on 100mg of 
brain tissue. DNA quality was assessed using the Agilent 2200 TapeStation DNA Integrity Number 
(mean=8.95) and quantified using Nanodrop 3300 spectrometry. Genotyping of 486,137 variants on 
the target dataset was performed on the customized NeuroChip array (Blauwendraat, et al., 2017). 
Quality control was completed using GenomeStudio2.0 (Illumina) and PLINK1.9 (Chang, et al., 
2015). Specifically, genotype clustering was completed with the assistance of a cluster file provided 
by Blauwendraat and colleagues (Blauwendraat, et al., 2017), further QC was based on low GenTrain 
score, low cluster separation score and low call rate (all < 0.5 in GenomeSudio).  The target dataset 
was aligned to the GRCh37/hg19 assembly in PLINK using files provided by Rayner, W (Personal 
correspondence, Nov 2017). Samples were removed based on call rate (<90%), gender mismatch, 
deviation from European population parameters and excess heterozygosity (±3 standard deviations 
from the mean). SNPs were removed from the target dataset based on call rate (<95%) and Hardy-
Weinberg equilibrium being greater than the Bonferroni corrected p-value threshold (1×10-7). 
Following quality control 484,402 SNPs remained. The APOE SNPs, rs7412 and rs429358, were 
genotyped with TaqMan assays using standard protocols. The same procedures were used for the 
validation dataset. 
2.3. GWAS dataset (IGAP) 
The β-statistic and p-values for 7,055,881 SNPs across the whole genome were extracted from a 
reference genome-wide dataset (Stage 1 meta-analysis of GWAS that included 74,046 subjects and 
was performed under the banner of IGAP (Lambert, et al., 2013). SNPs that lie within the 500kb 
region surrounding APOE (chr19:45160844-45660844; GRCh37/hg19 assembly) were excluded from 
the raw genotyped data but, since APOE was included in the synaptic gene list, the 2 SNPs that confer 
ε4 status (rs7412 and rs429358) were added back into the final GWAS dataset. There were 262,737 
SNPs common to the IGAP data and the NeuroChip.  
2.4. Synapse SNP set 
We retrieved a list of 537 genes that encode synaptic proteins from the GRCh37/hg19 reference 
assembly (UCSC genome browser Kent et al., 2002). The list (Supplementary Table 1) represents a 
conservative estimate of the synaptic proteome, according to criteria described in our previous study 
(Lleó, et al., 2019) that includes an established synaptic function and detection in synapse-enriched 
fractions from mouse, rat or human brain tissue. The 17,262 SNPs that lie within the synaptic gene 
regions were extracted using the PLINK1.9 extract function. SNPs that were not present on the 
Neurochip or in the GWAS dataset were removed. 227,015 SNPs present in the IGAP data for these 
537 genes were not available on the NeuroChip platform. We next applied the “Clumping” algorithm 
using PRSice-2 to the remaining 9,420 SNPs. This algorithm assigns an index SNP for each linkage 
disequilibrium (LD) block, defined as the SNP that showed the most significant association with AD 
(lowest p) in the IGAP sample dataset, and removes SNPs within 250kbp that showed strong pair-
wise LD (r2>0.1) with the index SNP. The 500kb region surrounding APOE was removed from the 
Neurochip dataset but, since APOE was included in the synaptic gene list, the 2 SNPs that confer ε4 
status (rs7412 and rs429358) were added back into the final synapse SNP set, which consisted of 
2,993 SNPs (Supplementary Table 2).  
2.5. Pathway enrichment analysis 
We extracted statistically over-represented biological processes, molecular function and cellular 
components annotated to the Synaptic PRS loci using the PANTHER online analysis tool (URL: 
http://www.pantherdb.org (Mi, et al., 2019)). Only ontologies with a false discovery rate (FDR) 
adjusted p-value <0.05 were imported into Cytoscape v3.71 (Shannon, et al., 2003) for cluster 
analysis using the ClusterOne function. 
2.6. Statistical Analysis 
PRS were calculated using PRSice-2 software (Choi and O'Reilly, 2019,Euesden, et al., 2015) as 
previously described (Chaudhury, et al., 2019). Figure 1 shows the PRS workflow. An unbiased 
threshold for p-values associated with the 2,993 SNPs in the GWAS dataset (testing from p<10-6 to 
p=1 in increments of 10-6) was used to prioritize SNPs that gave the best fitting PRS model (highest 
Nagelkerke r2 value). The β-statistic in the reference dataset was used to generate weighting estimates 
for each SNP. The weighted contribution of each SNP to the model is expressed as the β-statistic for 
that SNP / sum of the β-statistic of all SNPs in the model x 100. Empirical p-values were generated 
for the association of the model with LOAD over 10,000 iterations to minimize over-fitting (Choi and 
O'Reilly, 2019,Euesden, et al., 2015). Where specified, we included non-genetic predictors of LOAD 
(age-at-death and sex) using the covariates parameter in the PRSice-2 software. Mean PRS scores 
(two-tailed Students T test) and variance in PRS scores (Levene’s Test) were compared between 
LOAD and controls using IBM SPSS Statistics 25 software. We calculated p-values and odds ratios 
(OR) for association of individual SNPs in the Synaptic PRS model with LOAD using a Fisher’s 
exact association test employed in PLINK1.9. Receiver operating characteristic (ROC) curves were 
generated in R version 3.5.2 using the PRROC package (Grau, et al., 2015) to determine the accuracy 
(AUC) of the PRS models to predict LOAD. We used DeLong’s test (SPSS) to compare AUC 
between models.  
3. Results 
The BDR samples used in the target dataset included 137 controls and 302 pathologically confirmed 
LOAD patients. The mean age-at-death and male:female ratio were comparable between controls 
(83.7 years, standard deviation 9.9, 48% female) and LOAD patients (82.9 years, standard deviation 
8.5, p=0.4, 50% female, p=0.8). As expected, the percentage of APOE ε4 carriers was higher in 
LOAD patients (6566%) compared to controls (4016%, p<0.001).  
The optimal threshold for inclusion of SNPs from the restricted synapse SNP set (n=2,993) in the PRS 
model was p<10-6 (Nagelkerke’s r2=0.16, empirical p<0.001). The Table shows the individual 
association of the 8 SNPs that passed this threshold with LOAD both in the IGAP meta-analysis and 
in the independent BDR samples. The weighted contribution of each individual SNP to the PRS 
model is also shown. The 8 SNPs are located in 6 genes, of which APOE had the greatest contribution 
(combined weight for rs429358 and rs7412 = 67.8%), followed by DLG2 (9.9%) and BIN1 (combined 
weight for rs35114168 and rs17014923 = 9.4%), whereas MINK1, PICALM and PTK2B all 
individually contributed <5% weighting to the model. Figure 2A shows that the mean PRS was 2.3-
fold higher in LOAD compared with controls (p<0.0001) in the target dataset. Figure 2B compares 
the predictive accuracy of the Synaptic PRS with that of 3 other models; the Synaptic PRS + non-
genetic factors, the 2 SNPs that confer ε4 status (APOE E4) and the previously described Neurochip 
PRS (Chaudhury, et al., 2019), which comprises 167 SNPs + the 2 ε4 status SNPs. The Synaptic PRS 
predicted LOAD with 72.0% accuracy and was not improved by including non-genetic factors 
(difference=0.02%, p=0.8). Compared to APOE E4 (67.4%), the Synaptic PRS improved the accuracy 
by 4.6% (95% CI 2.5 to 6.7, p<0.0001). While the Synaptic PRS showed only a nominal 2.7% 
improvement (95% CI -1 to 7, p=0.2) over the Neurochip PRS, with 161 fewer SNPs, it represents the 
simplest PRS model with good accuracy to predict LOAD.  
We next tested the predictive capacity of the Synaptic PRS in an independent validation set of BDR 
samples that included 80 controls and 56 pathologically confirmed LOAD patients. The male:female 
ratio was comparable between controls (58% female) and LOAD patients (65% female, p=0.3) 
whereas the mean age-at-death was lower in LOAD (84.5, standard deviation=8.7) compared to 
controls (88.4, standard deviation=8.0, p=0.008). As expected, the percentage of APOE ε4 carriers 
was higher in LOAD patients (60%) compared to controls (16%, p<0.0001). Figure 2C shows that 
the mean Synaptic PRS was 3.6-fold higher in LOAD compared with controls (p<0.0001) in the 
validation dataset. Figure 2D shows that the Synaptic PRS predicted LOAD with 73.1% accuracy in 
the validation dataset, similar to the accuracy reported for the target dataset (72%). The predictive 
accuracy of the APOE E4 and Neurochip PRS in the validation dataset was 49.2% and 50.7%, 
respectively. However, it should be noted that due to missing genotype data, the Neurochip PRS for 
the validation dataset comprised 163 SNPs compared to 169 SNPs in the target dataset. 
Nevertheless, these data show that the Synaptic PRS represents the simplest PRS model with 
good accuracy to predict LOAD and has been replicated with comparable accuracy in two 
independent datasets. To determine whether the proteins encoded by the 8 Synaptic PRS loci have a 
shared function either within, or in addition to, their function at the synapse, we tested for over-
represented gene ontologies annotated to the 6 encoded proteins (Figure 3). The 6 proteins can be 
divided into two highly inter-related clusters; Cluster 1 (p=0.01) includes MINK1, DLG2, PTK2B and 
their shared annotations related to glutamate receptor signaling and ion transport. All 3 proteins within 
this cluster are annotated to the postsynapse and, specifically to the glutamatergic synapse. Cluster 2 
(p=0.005) includes APOE, PICALM, BIN1 and their shared annotations related to APP catabolism 
and tau protein binding and cellular component size and synapse.  PICALM and BIN1 are annotated 
to the presynapse, and specifically to the synaptic vesicle. APOE is annotated to the glutamatergic 
synapse. 
4. Discussion 
Here we report that a PRS based on 8 SNPs located in 6 genes that encode synaptic proteins shows 
improved (72.0%) predictive accuracy compared to the APOE locus (67.7%) in 137 controls and 302 
LOAD patients. Moreover the Synaptic PRS performed similarly to the previously reported 
Neurochip PRS (69.3%), which includes the 8 SNPs that comprise the Synaptic PRS or a proxy. The 
predictive accuracy of the Synaptic PRS was replicated (73.1%) in a second, independent dataset of 
80 controls and 56 LOAD patients. The elevated age-at-death of controls (88 years) relative to LOAD 
(85 years) in the validation cohort supports the idea that the Synaptic PRS is a predictor of 
AD and not normal aging. In summary, by limiting the PRS to just 8 SNPs that lie within synapse-
encoding regions, the Synaptic PRS represents the simplest PRS model with good accuracy (72 to 
73%) to predict LOAD Using the Synaptic PRS rather than the Neurochip PRS would therefore 
significantly reduce genotyping costs and allow simpler and faster data processing times with no 
effect on accuracy of the model. Of the 8 SNPs that form the Synaptic PRS, 2 lie in genes (MINK1 
and DLG2) that have yet to be associated with LOAD risk and were only nominally associated with 
AD in the reference GWAS (p<1x10-5). That being said, genetic variation in DLG2 has been 
associated with developmental disorders and intellectual disability (Reggiani, et al., 2017) and MINK1 
gene expression is altered in post-mortem AD brains (Broce, et al., 2019). These two SNPs combined 
accounted for 14.9% of the weighting in the Synaptic PRS model. The remaining 85.1% was 
contributed by loci that have previously shown replicable association with LOAD (Bertram, et al., 
2007), namely APOE (67.8% combined weighting), BIN1 (9.4% combined weighting), PTK2B (3.4%) 
and PICALM (4.5%), albeit that the SNPs were not the same as those identified in prior GWAS 
studies; rs17057043 (PTK2B) was in perfect LD (r2=1) with the PTK2B SNP (rs28834970) identified 
previously so likely reflects the same signal whereas BIN1 (rs17014923, r2<0.08 and rs35114168, 
r2<0.24) and PICALM (rs609903, r2<0.64) SNPs were not in strong LD with previously identified 
loci.   
As reported in our previous study (Lleo, et al., 2019), the proteins encoded by the 6 Synaptic PRS 
genes are all expressed at the cortical synapse and all have an established synaptic function. 
Specifically, MINK1 plays a critical role in AMPA receptor function (Hussain, et al., 2010). DLG2 
forms a postsynaptic scaffold for the clustering of receptors and ion channels (Nithianantharajah, et 
al., 2013) and is associated with glutamatergic dysfunction in major depressive disorder (Duric, et al., 
2013). PTK2B is involved in glutamatergic signaling and long-term potentiation (Giralt, et al., 2017). 
APOE plays a role in regulation of synaptic plasticity and AMPA receptor clustering (Valastro, et al., 
2001), dendritic spine formation (Nwabuisi-Heath, et al., 2014) and cholinergic sprouting (Bott, et al., 
2016). BIN1 is involved in postsynaptic trafficking (Yao, et al., 2010) and glutamatergic signaling 
(Schurmann, et al., 2019). PICALM is involved in synaptic vesicle maturation (Petralia, et al., 2013). 
Furthermore, we report here that these 6 proteins can be divided into two highly inter-related clusters 
enriched for functions associated with APP catabolism, tau protein binding and glutamate signaling, 
processes that are so fundamental to early AD pathophysiology (Gao, et al., 2018,Hardy and Selkoe, 
2002,Wang and Reddy, 2017) that they are the target of drugs currently in ongoing AD clinical trials 
(Aβ and tau accumulation) or are the target of therapies already prescribed for the treatment of AD 
symptoms (blockade of NMDA-mediated glutamate signaling). Overall these data support the 
recently proposed conceptualization of LOAD as a genetically driven synaptic failure (Dourlen, et al., 
2019).  
4.1. Conclusions 
The data reported here lend further support to the hypothesis that polygenic risk may account for 
some of the missing heritability in AD and that a pathway-targeted approach can result in PRS with 
high predictive accuracy for a relatively small number of variants. The relative simplicity of the 
Synaptic PRS without a concomitant drop in predictive capacity supports the hypothesis that synapse-
encoding genes are enriched for LOAD risk-modifying loci. While caution should be taken in 
interpreting these findings until they have been replicated in larger, independent datasets, our 
preliminary findings suggest that genetic variation in glutamate signaling, Aβ production and tau-
binding pathways may be important contributing factors to LOAD risk. Future studies into the 
functional relevance of these variants to these early AD pathways could shed further light into the 
genetic basis underlying their cumulative risk for LOAD and could lead to novel therapeutic 
strategies. The potential for these 8 polymorphisms as an accurate early screening tool to identify 
individuals at high-risk for developing AD before symptom onset would also be an interesting avenue 
worth pursuing.  
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Table 1. Association of the individual SNPs included in the Synaptic PRS model with LOAD. 
Locus   IGAP reference GWAS  Target dataset Contribution 
to model GENE SNP CHR BP Allele  MAF (AD;CTRLS) β p-value  MAF (AD;CTRLS) OR p-value 
BIN1 rs17014923 2 127841930 T  0.16;0.20 -0.1079 4x10-7  0.14;0.19 0.8 0.2 4.2% 
BIN1 rs35114168 2 127847930 A  0.40;0.32 0.1327 4x10-16  0.32;0.28 1.4 0.03 5.2% 
PTK2B rs17057043* 8 27220310 A  0.37;0.44 0.0882 1x10-7  0.37;0.41 1.3 0.07 3.4% 
PICALM rs609903 11 85740409 A  0.28;0.33 -0.1141 6x10-12  0.24;0.29 0.8 0.1 4.5% 
DLG2 rs286043* 11 85072958 C  0.02;0.004 0.2547 6x10-6  0.02;0.01 4.6 0.1 9.9% 
MINK1 rs8078173* 17 4763551 C  0.10;0.07 0.1279 3x10-6  0.09;0.07 1.5 0.1 5.0% 
APOE rs429358 19 45411941 C  0.39;0.19 1.3503 7x10-536  0.33;0.18 2.8 2x10-9 52.7% 
APOE rs7412 19 45412079 T  0.05;0.08 -0.3871 1x10-22  0.05;0.08 0.6 0.05 15.1% 
The summary statistics from the IGAP GWAS and Neurochip in the BDR dataset (p-value, OR, MAF) are shown.  




Figure 1. Study design and workflow.  
 
Figure 2. Synaptic PRS model as a predictor of LOAD. a) Mean and standard deviation of the 
polygenic risk scores for the best predictors from the synaptic gene list (Synaptic PRS) are plotted for 
the LOAD and healthy controls from the target (a) and validation (c) datasets. b) ROC curves plot the 
specificity and sensitivity of the Synaptic PRS and other models (see legend) to classify LOAD and 
healthy controls in the target (b) and validation (d) datasets. The Neurochip PRS comprises 169 SNPs 
for the target dataset and 163 SNPs for the validation dataset. c) Mean and standard deviation of the 
Synaptic PRS are plotted for the LOAD and healthy controls from the validation dataset. d) ROC 
curve plots the specificity and sensitivity of the Synaptic PRS to classify LOAD and healthy controls 




Figure 3. Enriched gene ontologies associated with proteins encoded by Synaptic PRS 
loci. Lines connect the Synaptic PRS loci (circular nodes) to the shared enriched biological processes 
and molecular functions to which they are annotated (all 25 to 100-fold enriched, all FDR adjusted p-
value <0.003). Node size and line thickness reflect the number of shared nodes. Rectangular boxes 
group the nodes according to shared enriched cellular components, which are labeled in bold (all 21 to 
62-fold enriched, all FDR adjusted p-value <0.01). The two highly inter-related clusters and 
associated p-values from cluster analysis are marked in blue (cluster 1) and red (cluster 2).  
8. Supplementary Material 
Table S1. Synapse Gene Set. Uniprot ID and names of proteins identified in (Lleo, et al., 
2019) as components of the synaptic proteome are given. The associated genes retrieved from 
the GRCh37/hg19 reference assembly are identified by chromosome (CHR), co-ordinate 
(FROM TO), EntrezGene ID and Gene names (primary and synonyms).  
Table S2. Synapse SNP set.  The rs numbers for SNPs that lie within the Synapse Genes and 
that were present on the Neurochip dataset and included in the IGAP GWAS (Lambert, et al., 
2013) are identified by chromosome (CHR), rs number (SNP) and base pair location (BP). The 
p-value for association of each SNP with LOAD in the IGAP dataset is also provided.  
 
 
